amphotericin B (topical): Definition, Uses, and Clinical Overview

amphotericin B (topical) Introduction (What it is)

amphotericin B (topical) is an antifungal medication used on the surface of the eye.
It is most often prepared as an eye-drop formulation for suspected or confirmed fungal eye infections.
In eye care, it is commonly discussed in the context of fungal keratitis (a corneal infection).
Because commercial ophthalmic products may be limited, it is frequently compounded by specialized pharmacies.

Why amphotericin B (topical) used (Purpose / benefits)

amphotericin B (topical) is used to treat infections caused by fungi on or near the front of the eye. The main goal is to reduce the fungal burden (the amount of fungal organisms), limit tissue damage, and support recovery of the ocular surface so vision is less likely to be affected.

Fungal eye infections can be challenging because they may:

• Progress more slowly than bacterial infections yet cause significant inflammation and scarring.
• Involve deeper corneal layers, making medication penetration important.
• Require prolonged treatment and close monitoring to confirm improvement.

In general terms, amphotericin B (topical) is selected when clinicians need an antifungal agent with activity against certain yeasts and fungi and when an eye-surface route (drops applied to the eye) is appropriate. The expected “benefit” is infection control, which can help preserve corneal clarity and reduce complications that may threaten vision.

Indications (When ophthalmologists or optometrists use it)

Typical scenarios include:

• Suspected fungal keratitis based on clinical appearance and risk factors (for example, after corneal trauma with plant material, contact lens–associated keratitis, or steroid exposure), when antifungal coverage is needed.
• Confirmed fungal keratitis after corneal scraping, culture, or microscopy identifies a fungal organism.
• Yeast-related keratitis (often discussed in connection with Candida species), where amphotericin B is commonly considered.
• Post-surgical or post-trauma fungal infection risk when fungal infection is part of the differential diagnosis (the list of possible causes).
• Adjunct therapy when a clinician is combining topical antifungals and/or systemic antifungals for more severe or deeper infections (the exact plan varies by clinician and case).
• Situations where other topical antifungals are unavailable or unsuitable, and a compounded option is used (availability varies by region and pharmacy).

Contraindications / when it’s NOT ideal

amphotericin B (topical) may be less suitable or avoided in situations such as:

• Known hypersensitivity or allergy to amphotericin B or components of the compounded formulation.
• Non-fungal causes of keratitis (bacterial, viral, allergic, toxic, or autoimmune), where an antifungal is unlikely to help and may delay appropriate therapy.
• Significant ocular surface toxicity or intolerance, such as marked worsening of redness, pain, or epithelial breakdown suspected to be medication-related (assessment and decisions vary by clinician and case).
• When a different antifungal is preferred for the likely organism, based on local practice patterns, lab results, or clinical features (choice varies by clinician and case).
• When compounding quality, sterility, or stability cannot be assured, since many topical amphotericin preparations are compounded and require careful handling (process varies by pharmacy and manufacturer).
• When deeper infection requires other routes (for example, intraocular involvement), because topical therapy alone may be insufficient (management varies by clinician and case).

How it works (Mechanism / physiology)

Mechanism of action (high level):
Amphotericin B is a polyene antifungal. In simplified terms, it targets fungal cell membranes by binding to a key membrane component (ergosterol). This disrupts membrane integrity and can lead to leakage and fungal cell death. Human cells contain cholesterol rather than ergosterol, which is one reason the drug can be selectively active against fungi, though irritation and toxicity can still occur on delicate eye tissues.

Relevant eye anatomy and tissues:
Topical drops primarily contact the:

• Tear film (the thin layer coating the eye)
• Conjunctiva (the membrane lining the eyelids and covering the white of the eye)
• Corneal epithelium (the cornea’s outer protective layer)

If a corneal ulcer is present, medication may reach deeper corneal layers more readily where the surface is disrupted. However, the cornea is still a barrier, and penetration to deep stromal infection can be limited. For severe infections, clinicians sometimes consider additional strategies (choice varies by clinician and case).

Onset, duration, and reversibility:
Topical amphotericin B does not work “instantly.” Improvement is usually assessed over time through repeated eye examinations, looking at ulcer size, depth, inflammation, and symptoms. The medication effect depends on consistent exposure at the ocular surface, so the “duration” is tied to dosing schedules and tear turnover. Any medication-related irritation typically improves after stopping or adjusting therapy, but infection-related scarring may be longer lasting.

amphotericin B (topical) Procedure overview (How it’s applied)

amphotericin B (topical) is a medication, not a surgical procedure. Still, its use usually follows a structured clinical workflow:

1. Evaluation / exam
   An eye care clinician evaluates symptoms (pain, light sensitivity, discharge, blurred vision) and examines the cornea with a slit lamp. If an ulcer is suspected, they assess size, depth, location, and whether there are signs pointing toward fungal infection.

2. Preparation (diagnostic steps and planning)
   If infection is suspected, clinicians may perform corneal scraping for microscopy and culture, because identifying the organism can influence medication choice. Not every case is scraped, and practice varies by clinician and setting.

3. Intervention (starting amphotericin B (topical))
   The medication is typically prescribed as compounded eye drops. Dosing frequency and duration are determined by the treating clinician based on severity, organism, and response.

4. Immediate checks
   Early follow-up is often used to confirm that the corneal surface is not deteriorating and that clinical signs are moving in the right direction. Clinicians may look for changes in the epithelial defect, infiltrate (the inflammatory/infectious area), and anterior chamber inflammation.

5. Follow-up (monitoring and adjustments)
   Subsequent visits track healing and complications (for example, persistent epithelial defects, corneal thinning, or scarring). Treatment may be adjusted, combined with other agents, or escalated if the infection is not responding (varies by clinician and case).

Types / variations

In ophthalmology, “types” of amphotericin B use usually refers to formulation and context, because amphotericin itself is a single active drug:

• Compounded topical eye drops
  Many clinics use amphotericin B (topical) as a compounded solution prepared from amphotericin B intended for other routes. Concentrations can vary (often described in low-percentage ranges), and the exact formulation depends on clinician preference, pharmacy protocol, and stability considerations.

• Compounded ophthalmic ointment (less common)
  Some settings may use ointment-based preparations. These can increase contact time on the ocular surface but may blur vision and be less comfortable for some people. Availability varies by pharmacy and region.

• Topical amphotericin B as monotherapy vs combination therapy
  In some cases it may be used alone; in others it is paired with another topical antifungal (such as an azole) or systemic antifungal medication. The choice depends on organism, depth of infection, and clinical response (varies by clinician and case).

• Topical vs non-topical amphotericin
  Amphotericin can also be given systemically (IV) or via intraocular routes in selected severe infections, but those are not topical approaches and involve different risk profiles and monitoring requirements.

Pros and cons

Pros:

• Targets fungi by a mechanism that differs from many other antimicrobial classes.
• Commonly recognized option for yeast-associated corneal infections in many clinical discussions.
• Can be used directly on the eye surface, delivering medication to the infected area.
• May be incorporated into a broader antifungal plan when infection is severe (varies by clinician and case).
• Familiar to many cornea specialists, with established clinical experience in ophthalmology practice.
• Allows treatment even when the goal is to avoid or delay surgery, if the infection is responsive.

Cons:

• Often requires compounding, which can affect availability, cost, and consistency (varies by pharmacy and region).
• Can cause ocular irritation (burning, redness, tearing) and surface toxicity in some patients.
• Topical penetration to deeper corneal tissue can be limited, especially when the surface is intact.
• May not be the preferred first-choice agent for every fungal organism (selection varies by clinician and case).
• Treatment courses for fungal keratitis can be prolonged, requiring frequent reassessment.
• Visual outcomes can still be limited by corneal scarring or irregularity even after infection control.

Aftercare & longevity

With amphotericin B (topical), “aftercare” typically means monitoring the eye’s healing and medication tolerance over time. Outcomes and how long treatment is needed depend on multiple factors:

• Severity and depth of infection
  Superficial keratitis may respond differently than deep stromal infection. Ulcers near the visual axis (the central cornea) can have greater impact on vision if scarring develops.

• Timing of diagnosis and organism type
  Earlier identification of fungal infection and organism-directed therapy can influence the course, but response varies by organism and individual factors.

• Ocular surface health
  Dry eye disease, eyelid inflammation (blepharitis), exposure problems, or poor tear quality can slow epithelial healing and increase discomfort.

• Medication tolerance and adherence
  Antifungal regimens can be demanding. Missed doses or early discontinuation can affect infection control, but dosing decisions should always be clinician-directed.

• Follow-up frequency and reassessment
  Clinicians typically reassess the cornea to confirm improvement and watch for complications like corneal thinning, persistent epithelial defect, or secondary infection.

• Comorbidities and medications
  Conditions such as diabetes or immune suppression can affect healing. Prior or ongoing corticosteroid exposure may also influence infection behavior; management decisions vary by clinician and case.

In general, “longevity” of results is less about the drug lasting in the body and more about whether the infection is fully controlled and how the cornea heals afterward (for example, whether scarring or irregular astigmatism remains).

Alternatives / comparisons

Choice of therapy for suspected fungal eye infection is individualized. Common comparisons include:

• amphotericin B (topical) vs natamycin (topical)
  Natamycin is often discussed as a commonly used topical option for filamentous fungal keratitis in many settings, while amphotericin B is frequently discussed for yeast coverage. The best fit depends on suspected organism, local availability, and clinician judgment (varies by clinician and case).

• amphotericin B (topical) vs topical azoles (e.g., voriconazole or other azole-class drops)
  Azole antifungals work through a different mechanism (inhibiting ergosterol synthesis rather than binding ergosterol). They are sometimes used when penetration or organism susceptibility is a concern. Selection and combination strategies vary by clinician and case.

• Topical therapy vs adding systemic antifungals
  Topical drops treat the ocular surface directly, while systemic therapy may be considered for deeper, extensive, or high-risk infections. Systemic therapy has broader body exposure and different side-effect considerations; whether it’s used depends on the clinical situation.

• Medication-only approach vs procedural escalation
  If the cornea is thinning, perforation risk is increasing, or infection is not responding, clinicians may consider procedures such as corneal debridement, tissue adhesives, or therapeutic corneal transplantation (keratoplasty). These decisions are time-sensitive and vary by clinician and case.

• Observation/monitoring vs immediate antifungal treatment
  Because fungal keratitis can threaten vision, clinicians often treat when suspicion is meaningful, but diagnostic certainty and risk tolerance vary. Monitoring alone may be considered when fungal infection is unlikely, but this is a clinician-driven decision.

amphotericin B (topical) Common questions (FAQ)

Q: What is amphotericin B (topical) used for in eye care?
It is mainly used for fungal infections affecting the front of the eye, especially fungal keratitis (corneal infection). It is usually considered when fungi are suspected or confirmed on testing. The exact choice depends on the organism and clinical picture.

Q: Does amphotericin B (topical) hurt or burn when applied?
Some people experience stinging, burning, tearing, or redness after drops are placed. This can come from the medication itself or from the already-inflamed ocular surface. Comfort varies widely by individual and formulation.

Q: How quickly should symptoms improve?
Fungal keratitis often improves gradually rather than overnight. Clinicians look for objective signs on examination (changes in the ulcer, infiltrate, and inflammation) over repeated visits. The timeline varies by organism, depth of infection, and overall eye health.

Q: Is amphotericin B (topical) “safe” for the eye?
It is used in ophthalmology because it can be effective against certain fungi, but it can also irritate the eye and affect the corneal surface. Safety is monitored through follow-up exams that assess healing, toxicity, and complications. Risk–benefit decisions vary by clinician and case.

Q: Can I drive or use screens after using amphotericin B (topical)?
Right after instilling drops, temporary blur and tearing can occur, which may affect driving or detailed visual tasks. Screen use is usually possible, but comfort can be limited by light sensitivity or irritation from the underlying infection. Practical impact varies by person and severity.

Q: How long does treatment usually last?
Treatment length depends on how severe the infection is, how deep the cornea is involved, and how the eye responds. Fungal infections often require longer courses than many bacterial infections. The end point is typically guided by clinical exams rather than a fixed duration.

Q: Is amphotericin B (topical) expensive?
Cost can vary substantially because many formulations are compounded and pricing depends on pharmacy, region, and insurance coverage. Additional costs may include frequent follow-up visits and diagnostic testing. Your clinic or pharmacy can explain typical local pricing.

Q: Can I wear contact lenses while using amphotericin B (topical)?
Contact lenses are commonly avoided during active keratitis because they can worsen irritation, interfere with healing, and increase infection risk. Whether and when lenses can be worn again depends on corneal healing and clinician assessment. Recommendations vary by clinician and case.

Q: Why might my clinician choose a different antifungal instead?
Different antifungals have different activity profiles and tissue-penetration characteristics. If lab testing identifies a specific organism, therapy may be tailored accordingly. Availability and tolerance also influence the choice.

Q: Will amphotericin B (topical) prevent scarring or vision changes?
Controlling the infection helps reduce ongoing tissue damage, but corneal scarring or irregularity can still occur, especially with deeper or central ulcers. Visual recovery depends on where the ulcer is, how it heals, and whether complications develop. Outcomes vary by clinician and case.